RT Journal Article
T1 Clinical Subgroups in Bilateral Meniere Disease.
A1 Frejo, Lidia
A1 Soto-Varela, Andres
A1 Santos-Perez, Sofía
A1 Aran, Ismael
A1 Batuecas-Caletrio, Angel
A1 Perez-Guillen, Vanesa
A1 Perez-Garrigues, Herminio
A1 Fraile, Jesus
A1 Martin-Sanz, Eduardo
A1 Tapia, Maria C
A1 Trinidad, Gabriel
A1 García-Arumi, Ana María
A1 González-Aguado, Rocío
A1 Espinosa-Sanchez, Juan M
A1 Marques, Pedro
A1 Perez, Paz
A1 Benitez, Jesus
A1 Lopez-Escamez, Jose A
K1 Meniere’s disease
K1 autoimmune disorders
K1 cluster analysis
K1 hearing loss
K1 inner ear
K1 migraine
K1 tinnitus
K1 vestibular disorders
AB Meniere disease (MD) is a heterogeneous clinical condition characterized by sensorineural hearing loss, episodic vestibular symptoms, and tinnitus associated with several comorbidities, such as migraine or autoimmune disorders (AD). The frequency of bilateral involvement may range from 5 to 50%, and it depends on the duration of the disease. We have performed a two-step cluster analysis in 398 patients with bilateral MD (BMD) to identify the best predictors to define clinical subgroups with a potential different etiology to improve the phenotyping of BMD and to develop new treatments. We have defined five clinical variants in BMD. Group 1 is the most frequently found, includes 46% of patients, and is defined by metachronic hearing loss without migraine and without AD. Group 2 is found in 17% of patients, and it is defined by synchronic hearing loss without migraine or AD. Group 3, with 13% of patients, is characterized by familial MD, while group 4, that includes 12% of patients, is associated by the presence of migraine in all cases. Group 5 is found in 11% of patients and is defined by AD. This approach can be helpful in selecting patients for genetic and clinical research. However, further studies will be required to improve the phenotyping in these clinical variants for a better understanding of the diverse etiological factors contributing to BMD.
SN 1664-2295
YR 2016
FD 2016-10-24
LK https://hdl.handle.net/10668/28408
UL https://hdl.handle.net/10668/28408
LA en
DS RISalud
RD Apr 6, 2025